Thanks, Todd. Good morning, everyone. We're pleased with our third-quarter results. Sales were up due to the strong foundation of recurring revenue and the diverse mix of businesses and geographies where we operate. Profit was up due to revenue growth, expense discipline, and prioritized investments, and we made notable contributions to shareholders via repurchase, and our recently announced dividend increase. I want to thank my colleagues around the world who stay focused on our customers and our opportunities for growth amidst this uncertain environment. It's no easy task, and they do these things while keeping a close eye on expenses profitability, and cash. Which makes us the strong company we are. Before going through the details on our performance, I want to touch on the charge we took in the quarter for an impairment of intangible assets. The charge relates to our two upstream bioprocessing businesses, Universal Technologies and Solaris. As we have discussed over the last several quarters, results have been pressured by market headwinds, including weak capital spending, and longer-than-expected drug development timelines. The situation has not improved, with an elongated ramp-up in sales and profitability ultimately leading to an impairment. That said, we still believe the bioprocessing market presents great opportunities for us. And we will continue to make strategic investments as we look for ways to develop and commercialize new disruptive technologies. Now turning to a few highlights from the quarter. Note that my profit comments will exclude the impact from the items Sarika referenced earlier. Total sales increased 1%. Driven by pricing and volume growth, partially offset by a headwind from currency translation. Expense leverage drove operating margin up 80 basis points. And adjusted EPS of $0.99 was 8% above the prior year. Going further into the P and L, we gross margin was 34.5% a decrease of 110 basis points from last year mainly as a result of higher manufacturing costs. Including those related to footprint optimization initiatives. While these projects pressure gross margin in the near term, we are confident they will enhance our long-term profitability. I also want to repeat a point Todd made about tariffs. The impact on gross margin in the third quarter was negligible. And the total annualized impact from the current tariffs is estimated at less than 1% of sales, which is something we believe we can offset. We recognize the importance of this topic, so we wanted to make it clear where we stand today. Back to the P and L. Third-quarter operating expense as a rate of sales improved to 18.2% from 20.1% a year ago. The favorability was driven by a handful of things. business within life sciences. We had a reversal of an earn-out reserve for our Purologic And and we also had lower warranty expense. These factors were further complemented by our ongoing expense discipline. Reflecting the sharp prioritization happening across the company. In terms of segment profitability, Mobile Solutions pretax profit margin was 18.1%, down 30 basis points year over year, mainly due to higher manufacturing costs. And including those related to footprint optimization projects. Industrial solutions pretax margin was also 18.1%. Down 60 basis points. Largely as a result of unfavorable regional end product sales mix. Life sciences pretax margin improved notably to 7.8% mainly due to the previously mentioned earn-out reversal for PureLogix, which resulted from a longer-than-expected revenue cycle. Life sciences profit margin also benefited from the cost optimization initiatives launched earlier this year. While we expect market-based headwinds in our bioprocessing business to continue, we are committed to making selective strategic investments while leveraging the strength of our more mature life sciences businesses. Now our updated fiscal 2025 outlook. First on sales. We are projecting a full-year total sales increase between 1% and 3%. In line with our prior guidance. Pricing is expected to contribute approximately 1% and the impacts from both currency translation and tariffs are expected to be negligible. For mobile solutions, where forecasting sales will be flat, to up 2% consistent with our previous expectation as higher margin aftermarket growth, is being partially offset by ongoing first fit pressure. We did modify the on-road forecast with continued weakness in global truck production resulting in a sales decline in the high teens versus low double digits. As a side note, I know transportation markets get a lot of attention due to the availability of public data. But I want to remind everyone that the on-road first fit part of our business hovers between only 3% and 5% of total sales. We like this space, and our deep customer relationships give us confidence that our advanced technologies are excellent solutions now and into the future, but it's important to keep perspective on the impact these truck cycles have on our business. Moving to off-road, the sales guidance of a mid-single-digit decline stayed the same. Primarily due to weak agriculture markets. Our guidance for aftermarket sales is also unchanged. At a low single-digit increase versus the prior year. Showing the resilience of this important category of business. In industrial solutions, sales are forecast to grow between 2% and 4%. In line with our previous expectation. We continue to expect IFS sales to increase low single digits with replacement part growth offsetting slower sales of new equipment. Which are being pressured by the uncertain economic environment. Aerospace and defense sales are now projected to increase in the low teens up from high single digits as robust market conditions in both aerospace and defense continue. In life sciences, our expectation of high single-digit growth is unchanged. The positive momentum in our larger legacy businesses, disc drive and food and beverage, continues to be partially offset by ongoing weakness in bioprocessing. Consistent with the guidance we laid out at the beginning of the year, we are forecasting full-year segment profitability to be roughly breakeven. From a total company perspective, we are maintaining our forecast operating margin at record levels, between 15.6% and 16.0%. At the midpoint, this would be a 40 basis point year-over-year expansion. Largely as a result of our continued focus on expense management. Our adjusted EPS guidance of $3.64 to $3.70 also reflects a record level. At the midpoint, we raised our forecast $0.03 from our previous guidance. Implying a solid 7% year-over-year EPS increase that is built on a 2% sales increase. Despite the economic environment, we demonstrate our ability to drive leverage conditions become more robust. and we believe we could further expand that leverage when the economic In the meantime, we control what we can. Including those key aspects of capital deployment. Ash conversion is expected to be in the range of 80% to 90% this year. Consistent with historical averages. We look to finish the year with fourth-quarter conversion higher than year-to-date levels due to normal seasonality and a reduction in working capital. Primarily through lower inventory levels as our teams continue to navigate certain supply chain issues. And then at a high level, strategic capital deployment is always on our minds. Investing for growth remains the top priority. We see opportunities within the company and outside via acquisitions. Inside the company, our capital expenditures for this year are forecast between $75 million and $90 million We are investing in future growth through capacity expansion, new product development, and technology projects. M and A is also an important lever in supporting our future growth. And we are still actively working a pipeline of opportunities. We are strategic and disciplined. With our focus remaining more squarely on opportunities within the life sciences and industrial markets. But the timing of deals can be uncertain. And that guides our actions. We have to protect some level of liquidity to give us flexibility to act when the opportunity arises. And we do this well given the incredible strength of our balance sheet. At the same time, we're committed to the ongoing return of cash to shareholders in a thoughtful and systematic manner. I want to provide a couple of updates on that point. First, as Todd mentioned, last week, we announced an 11% increase in our quarterly cash dividend. This level of increase is a testament to our strong operating performance today and our confidence in our future performance and financial strength. It's also worth highlighting that 2025 is forecast to be Donaldson's 30th year in a row. Of annual dividend increases. It's a massive accomplishment. And limited to a small number of great companies. Including our peers in the S and P high yield dividend aristocrat index. We are proud to be part of this elite group. My second point on returning cash to shareholders during the third quarter, we repurchased 2.4% of our outstanding shares for a total of $192 million bringing our year-to-date repurchase to 3.3% of outstanding shares. With that level of buyback, we are now increasing our full-year expectation to between 3.5% and 4%. Dividends and share repurchase are longstanding components of our capital deployment priorities. And through these vehicles, we demonstrate our view that Donaldson has a strong foundation and excellent long-term growth prospects. In summary, we performed well so far this year, The outlook we provided today suggests that performance continues in fourth quarter, in fiscal 2025. keeping us on track to deliver record sales and adjusted earnings Now I'll turn the call back to Todd.